Some drug makers are pegging how much insurance companies pay for their drugs to how effective they are for individual patients, Andrew Pollack reports. Merck is expected to announce today, for
example, that it has agreed to tie what Cigna pays for the diabetes drugs Januvia and Janumet to how well Type 2 diabetes patients are able to control their blood sugar.
Read the whole story at New York Times »